Introduction {#sec1}
============

Autoimmune diseases (ADs) are a major health issue worldwide, affecting nearly 10% of the population \[[@B1]\]. Human ADs are often complex diseases caused by the interplay of genetic and environmental factors \[[@B2]\]. It has been widely reported that several different ADs share a significant genetic background \[[@B3]\]. A growing body of evidences suggests that T-cell immunoglobulin and mucin domain (TIM) proteins participate in both the regulation of helper T-cell immune response and in ADs \[[@B6]\].

TIM-3 is a negative regulator of immune responses and can be expressed on activated Th1 cells, CD8^+^ T cells and at a low level on Th17 cells \[[@B13]\]. These cells produce decreased amounts of cytokines or are less proliferative when TIM-3 is activated by galectin-9 \[[@B16],[@B17]\]. Blockade of the TIM-3 signaling pathway restores proliferation and enhances cytokine production in vaccine-induced CD8^+^ T cells \[[@B18]\]. TIM-3 also induces peripheral tolerance through interacting with galectin-9, revealing an inhibitory action on T-cell responses \[[@B19],[@B20]\].

Several studies have demonstrated that TIM-3 polymorphism could be associated with ADs, such as multiple sclerosis (MS), Graves' disease (GD), Hashimoto's disease (HD), autoimmune thyroid diseases (AITDs), ankylosing spondylitis (AS), idiopathic thrombocytopenic purpura (ITP), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) \[[@B21]\]. Results, however, have been inconsistent, possibly due to the low statistical relevance of the individual studies. We, therefore, present a meta-analysis of the published data in order to evaluate the possibility of association between TIM-3 rs1036199 (4259 G/T) polymorphism and AD susceptibility.

Materials and methods {#sec2}
=====================

Literature search strategy {#sec2-1}
--------------------------

For the meta-analysis, PubMed, Web of Science and Embase databases were searched without language limitations. The final search was performed on July 7, 2018, using search terms: 'T cell immunoglobulin and mucin domain 3 OR TIM-3 OR 4259 G/T OR rs1036199', 'autoimmune diseases OR autoimmunity' and 'polymorphism OR variant'. In order to identify additional eligible studies, references from all relevant articles were also included.

Inclusion criteria {#sec2-2}
------------------

Selection criteria were independently assessed by two researchers, based on several factors. First, assessment of the association between TIM-3 rs1036199 and ADs; second, only case--control studies were included, and finally that sufficient genotype data were available for odds ratio and confidence interval calculations. Agreement was reached via discussion in the case of any conflicts.

Data extraction {#sec2-3}
---------------

Data were extracted from the eligible studies by two independent researchers. The following data types were extracted: the first author, publication year, country, ethnicity, disease type, genotyping method, source of control, total number of cases and controls, Hardy--Weinberg equilibrium and amount of cases and controls for every genotype. Any dispute was resolved by discussion.

Statistical analysis {#sec2-4}
--------------------

The Chi-squared test was used to examine the Hardy--Weinberg equilibrium within the control group, with *P*\<0.05 considered as a statistically significant disequilibrium. Odds ratio (OR) and 95% confidence interval (CI) were calculated to assess the association between TIM-3 rs1036199 polymorphism and ADs. Pooled OR results were derived from the combination of each study through comparison in allelic (G versus T) and heterozygote (GT versus TT) models. A Z-test was used to determine pooled OR results, and a *P* value \<0.05 was considered significant. Heterogeneity was assessed using a standard *Q*-statistic test and an *I*^2^ test was used to quantify inconsistency. If the *P*-value of the *Q*-test was less than 0.1, or an *I*^2^ value \>50%, ORs were pooled according to the random-effective model. Otherwise, the fixed-effective model was employed. Sensitivity analyses were conducted toward every genetic model to assess the influence of each individual study on combined ORs by sequentially deleting each study. Additionally, subgroup analysis was stratified by disease, ethnicity and source of control. Publication bias was evaluated by Egger's test and Begg's funnel plots. All statistical analyses were performed using STATA software, version 14.0 (StataCorp, College Station, TX).

Results {#sec3}
=======

Literature review and description of included studies {#sec3-1}
-----------------------------------------------------

The study selection process is illustrated in [Figure 1](#F1){ref-type="fig"}. In total, 246 relevant studies with the TIM-3 rs1036199 polymorphism and AD were identified through PubMed, Embase and Web of Science. Initially, 38 publications were excluded due to duplication. Next, 191 studies were removed after screening the titles and abstracts. Subsequently, 17 articles were evaluated by reading the full-text and 8 articles were removed because of incomplete or irrelevant data focusing on other TIM-3 polymorphisms \[[@B21],[@B25],[@B27],[@B31]\]. Finally, 9 publications meeting the inclusion criteria were selected \[[@B22],[@B26],[@B28],[@B36],[@B37]\]. In addition, one article included two case--control studies featuring different populations \[[@B24],[@B30]\], so in total, 10 eligible studies, amounting to 2166 ADs and 2034 controls, were enrolled. These investigations presented data on several different autoimmune disease types, such as MS, GD, AITDs, AS, RA and ITP. Among the 10 studies, 9 were conducted in Asian populations and 1 in an African population. The genetic distributions of the control groups in all investigations were consistent with the Hardy--Weinberg equilibrium. The characteristics of the selected investigations are summarized in [Table 1](#T1){ref-type="table"}.

![Process of study selection in this meta-analysis](bsr-38-bsr20181235-g1){#F1}

###### Characteristics of the included studies

  Study                  Year   Country      Ethnicity   Diseases   Genotyping   Source of controls   Case   Control   HWE                  
  ---------------------- ------ ------------ ----------- ---------- ------------ -------------------- ------ --------- ----- ----- ---- --- -------
  Pouladian \[[@B35]\]   2017   Iran         Asian       MS         RFLP         HB                   102    34        4     116   21   1   0.963
  Inoue \[[@B22]\]       2017   Japan        Asian       AITDs      RFLP         HB                   273    14        0     66    4    0   0.806
  Wang \[[@B27]\]        2014   China        Asian       AS         RFLP         HB                   262    20        0     279   19   0   0.570
  Liang \[[@B24]\]       2012   China        Asian       GD         PCR-SSP      PB                   172    10        0     147   3    0   0.902
  Xu \[[@B28]\]          2011   China(Hui)   Asian       RA         PCR-SSP      PB                   198    28        0     224   7    0   0.815
  Xu \[[@B28]\]          2011   China        Asian       RA         PCR-SSP      PB                   90     13        0     103   5    0   0.806
  Song \[[@B26]\]        2011   China        Asian       RA         TaqMan       HB                   335    31        0     365   24   0   0.530
  Radwan \[[@B34]\]      2011   Egypt        African     ITP        RFLP         PB                   62     35        0     131   68   9   0.963
  Du \[[@B21]\]          2009   China        Asian       ITP        RFLP         HB                   178    9         0     120   3    0   0.891
  Chas \[[@B20]\]        2004   Korea        Asian       RA         SBE          PB                   203    93        0     256   63   0   0.050

Abbreviations: AITD, autoimmune thyroid disease; AS, ankylosing spondylitis; GD, Graves' disease; HB, hospital-based; HWE, Hardy--Weinberg equilibrium of controls; ITP, idiopathic thrombocytopenic purpura; PB, population-based; PCR-SSP, polymerase chain reaction with sequence specific primers; RA, rheumatoid arthritis; RFLP, restriction fragment length polymorphism.

Quantitative data synthesis {#sec3-2}
---------------------------

The results are displayed in [Table 2](#T2){ref-type="table"}. In the overall analysis, TIM-3 rs1036199 polymorphism was associated with an increased risk of ADs in allelic (G versus T: OR = 1.59, 95%CI: 1.17--2.17, [Figure 2](#F2){ref-type="fig"}A) and heterozygous models (GT versus TT: OR = 1.68, 95%CI: 1.37--2.06, [Figure 3](#F3){ref-type="fig"}A). As shown in [Table 2](#T2){ref-type="table"}, no significant heterogeneity was found in the heterozygous model (*P*=0.142, *I*^2^ = 33.3%), but slight heterogeneity was found in allele model (*P*=0.030, *I*^2^ = 51.3%). Subsequently, subgroup analysis was conducted by ethnicity, source of control and disease type. When subgroup analysis was performed based on ethnicity, significant correlation was detected between rs1036199 polymorphism and increased risk of ADs in Asian populations (G versus T: OR = 1.76, 95%CI: 1.43--2.18; GT versus TT: OR = 1.82, 95%CI: 1.46--2.28, [Figures 2](#F2){ref-type="fig"}B and [3](#F3){ref-type="fig"}B), but not in African populations. When results were stratified by source of controls, increased risk of AD was detected in both population-based studies (G versus T: OR = 1.93, 95%CI: 1.08--3.45; GT versus TT: OR = 2.10, 95%CI: 1.28--3.43, [Figures 2](#F2){ref-type="fig"}C and [3](#F3){ref-type="fig"}C) and in hospital-based studies (G versus T: OR = 1.45, 95%CI: 1.07--1.97; GT versus TT: OR = 1.41, 95%CI: 1.02--1.94, [Figures 2](#F2){ref-type="fig"}C and [3](#F3){ref-type="fig"}C). Moreover, significant associations were reached in the subgroup of rheumatoid arthritis using the two genetic models (G versus T: OR = 1.88, 95%CI: 1.45--2.44; GT versus TT: OR = 2.02, 95%CI: 1.53--2.65, [Figures 2](#F2){ref-type="fig"}D and [3](#F3){ref-type="fig"}D).

![Forest plot of OR with 95% CI for TIM-3 rs1036199 polymorphism and AD risk in allele model (G vs T)\
(**A**) Overall results; (**B**) stratified analysis by ethnicity; (**C**) subgroup analysis by design of study; (**D**) stratified analysis by AD types.](bsr-38-bsr20181235-g2){#F2}

![Forest plot of OR with 95% CI for TIM-3 rs1036199 polymorphism and AD risk in heterozygote model (GT vs TT)\
(**A**) Overall results; (**B**) stratified analysis by ethnicity; (**C**) subgroup analysis by design of study; (**D**) stratified analysis by AD types.](bsr-38-bsr20181235-g3){#F3}

###### Summary of OR and 95% CI values for TIM-3 rs1036199 polymorphism and AD risk

                               G vs T                  GT vs TT                             
  ----------------------- ---- ----------------------- ------------ ----------------------- ------------
  Total                   10   **1.59 (1.17--2.17)**   0.030/51.3   **1.68 (1.37--2.06)**   0.142/33.3
  **Ethnicity**                                                                             
  Asian                   9    **1.76 (1.43--2.18)**   0.257/21.0   **1.82 (1.46--2.28)**   0.237/23.1
  African                 1    --                      --           **--**                  --
  **Source of control**                                                                     
  HB                      5    **1.45 (1.07--1.97)**   0.577/0.0    **1.41 (1.02--1.94)**   0.685/0.0
  PB                      5    **1.93 (1.08--3.45)**   0.004/74.2   **2.10 (1.28--3.43)**   0.046/58.7
  **Disease type**                                                                          
  RA                      4    **1.88 (1.45--2.44)**   0.120/48.6   **2.02 (1.53--2.65)**   0.123/48.1
  Others                  6    1.23 (0.94--1.61)       0.147/38.8   **1.35 (1.00--1.83)**   0.511/0.0

Abbreviations: HB, hospital-based; *N*, number of studies; *P, P* value of *Q*-test for heterogeneity; PB, population-based.

Sensitivity analysis {#sec3-3}
--------------------

Sensitivity analysis was conducted to investigate the individual study's effect on the pooled ORs. After every individual study was sequentially excluded from the pooled analysis, the results indicated that there was no remarkable change of data for the two models ([Figure 4](#F4){ref-type="fig"}A,B). This provided evidence of the consistency of the results.

![Sensitivity analysis of association between TIM-3 rs1036199 polymorphism and AD risk. (A) allele model; (B) heterozygote model.](bsr-38-bsr20181235-g4){#F4}

Publication bias {#sec3-4}
----------------

Begg's funnel plots were performed to assess any possible publication bias, and no obvious asymmetry evidence was found according to the shape of the funnel plots ([Figure 5](#F5){ref-type="fig"}A,B). Subsequently, Egger's linear regression was utilized to quantitatively estimate the publication bias, the *P*-value of Egger's test indicated a lack of publication bias for rs1036199 polymorphism (*P*=0.374 for the allelic genetic model; *P*=0.510 for the heterozygous genetic model).

![Begg's funnel plot evaluating evidence of publication bias from the eligible studies. (A) allele model; (**B**) heterozygote model.](bsr-38-bsr20181235-g5){#F5}

Discussion {#sec4}
==========

TIM-3 gene is located on chromosome 5q33.2 and is mainly expressed in Th1 cells \[[@B38]\]. The TIM-3--galectin-9 signaling pathway induces cell death and ends the Th1 response at tissue sites \[[@B39]\]. Given that TIM-3 can reduce the antigen-specific T-cell responses, we speculate that TIM-3 polymorphism conferred individual risk for ADs by increasing TIM-3 expression and/or enhancing TIM-3 activity.

The 4259 G/T polymorphism is located within exon 3 of TIM-3. A switch from T to G leads to the amino-acid substitution of arginine by leucine \[[@B40]\]. The effects of amino acid substitution at this site remain unclear. Perhaps the amino acid substitution arising from the SNP leads to the alteration of TIM-3 structure and thus influences the immune function of the cell. The variation may also affect the susceptibility to ADs. Most SNPs are associated with more than one autoimmune disease, indicating shared immunological pathways that are disrupted when immune tolerance is broken \[[@B3]\]. However, relatively few studies were conducted on the association between autoimmune diseases and other TIM-3 SNPs. For example, only two publications investigate the relationship between TIM-3 -1541C\>T polymorphism and autoimmune diseases \[[@B27],[@B30]\].

To the best of our knowledge, no previous meta-analysis has comprehensively investigated the association between rs1036199 polymorphism and AD risk. Our analysis revealed that TIM-3 rs1036199 polymorphism was significantly associated with an increased overall risk of AD. The AD risk was markedly more pronounced in Asian populations using allelic and heterozygous genetic models. Subgroup analyses based on disease type further revealed that TIM-3 rs1036199 polymorphism was only associated with an increased risk of rheumatoid arthritis and might have no effect on GD or ITP.

There are, however, some limitations to the meta-analysis. First, for several ADs, the sample of studies is small, which may lead to insufficient power to detect a slight association. Second, most of the investigations analyzed were conducted on Asian populations, so further investigation into other ethnic populations is required. In addition, more eligible investigations on different kinds of autoimmune disease are recommended.

In conclusion, our analysis indicates that TIM-3 rs1036199 polymorphism increases the susceptibility to AD in the overall population and in Asian populations. In particular, it shows that the TIM-3 rs1036199 polymorphism is associated with an increased genetic susceptibility to rheumatoid arthritis.
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